Older adults' sexuality and sexual expression are often overlooked in nursing home and residential care settings. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Hospice use over 2 weeks was associated with decreased hospital days (1-5 days overall, with greater decreases for longer hospice use) for all beneficiaries; spending was $900-$5,000 less for hospice use of 31-90 days for most beneficiaries not in nursing homes, except beneficiaries with Alzheimer's. Overall spending decreased with hospice use for beneficiaries in nursing homes with lung cancer only, with a $3,500 reduction. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Adjunctive florbetapir-PET increased quality-adjusted life years (QALYs) by 0.008 years and increased costs by 36 compared to SCE alone (incremental cost-effectiveness ratio [ICER], 4,769). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Care of dementia is extremely resource demanding and has a great impact on both the formal care systems and the situation for informal carers. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Average annual cost among patients diagnosed with dementia was €43,259, primarily incurred by accommodation. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma SAH levels and atherosclerotic lesion size were significantly increased in adenosine dialdehyde and SAH hydrolase short hairpin RNA groups when compared with control group. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).ObjectiveThis study aims to evaluate the social value of lecanemab in Japan. 1 key finding →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among SNF admissions from 2013 to 2018, the share of ACO-attributed beneficiaries increased from 7.6% to 20.2%, MA enrollees increased from 25.2% to 32.8%, and non-ACO-attributed TM enrollees decreased from 67.2% to 47.3%. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The No coverage group had a 38% increase in the odds ratio of any use of antidementia medications (P = 0.0008) post-Part D relative to the No cap group. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We examined the real-world utilization and persistence of rapid acting insulin (RAI) in elderly patients with type 2 diabetes who added RAI to their drug (OAD) regimen. 2 key findings →
Participants: 3,734 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Centers for Medicare and Medicaid Services (CMS) administrative data are among the most practical sources for understanding the incidence of dementia over time in older populations, but have yet to be widely used in intervention studies. 1 key finding →
Participants: 135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There were no significant differences in self-efficacy related to obtaining respite and RDPB between SES groups. 5 key findings →
Participants: 144 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
What is already known about this topic?: Dementia leads public health issues worldwide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found significant county-level variability in utilization of high-quality home health. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Artificial intelligence (AI) is rapidly expanding into dementia-related health and social care, with proposed applications ranging from early risk detection and monitoring to care coordination and service planning. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
To examine telehealth adoption and discontinuation by home health agencies (HHAs) during the COVID-19 pandemic in the context of telehealth pre-pandemic diffusion into the industry and its continued use once the pandemic abated. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Since 2007, the Medicare Severity Diagnosis Related Groups classification system has favored billing codes for acute encephalopathy over delirium codes in determining hospital reimbursement and several quality-of-care value metrics, despite broad overlap between these sets of diagnostic codes. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Failure to perform same-admission cholecystectomy (SA-CCY) for mild, acute, biliary pancreatitis (MABP) is a recognized risk factor for recurrence and readmission. 3 key findings →
Participants: 578 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Enrollment in Medicare Advantage (MA) has been rapidly growing. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
36/100
Primary analysis calculated the impact of increasing the use of mirabegron from 4.5% to 5.3%, 7.1%, and 9.4% in years 1, 2, and 3, respectively, among oral pharmacological OAB treatments that included generic and branded antimuscarinics: oxybutynin, tolterodine, trospium, darifenacin, fesoterodine, and solifenacin. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Closing the gap substantially reduced individuals' out-of-pocket spending, and the reduction was larger for those with more severe mental disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Uncertainty surrounds cholinesterase inhibitor (ChEIs) effectiveness in mild to moderate Alzheimer Disease (AD). 2 key findings →
Participants: 2,678 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
8 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation
- Social determinants of health in total knee arthroplasty : are social factors associated with increased 30-day post-discharge cost of care and length of stay?
- Single nucleus multiomics identifies ZEB1 and MAFB as candidate regulators of Alzheimer's disease-specific cis-regulatory elements
- The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
- Cognitive Assessment At Medicare’s Annual Wellness Visit In Fee-For-Service And Medicare Advantage Plans
- The cost of cerebral ischaemia
- Cost-effectiveness of amyloid-targeting therapies in a memory clinic population; a simulation study
- Continuity of Care and Health Care Utilization in Older Adults With Dementia in Fee-for-Service Medicare
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →